$1.35
0.74% today
Nasdaq, Aug 12, 10:03 pm CET
ISIN
US3741631036
Symbol
GERN

Geron Corporation Stock price

$1.35
+0.01 0.75% 1M
-1.44 51.61% 6M
-2.19 61.86% YTD
-3.38 71.46% 1Y
-1.00 42.55% 3Y
-0.29 17.68% 5Y
-2.10 60.87% 10Y
-7.94 85.47% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
-0.01 0.74%
ISIN
US3741631036
Symbol
GERN
Industry

Key metrics

Basic
Market capitalization
$867.7m
Enterprise Value
$598.7m
Net debt
positive
Cash
$388.0m
Shares outstanding
637.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
5.3 | 4.3
EV/Sales
3.6 | 3.0
EV/FCF
negative
P/B
3.3
Financial Health
Equity Ratio
47.2%
Return on Equity
-62.3%
ROCE
-16.1%
ROIC
-
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$164.5m | $199.5m
EBITDA
$-78.0m | $-80.6m
EBIT
$-79.1m | $-79.3m
Net Income
$-88.0m | $-82.4m
Free Cash Flow
$-178.3m
Growth (TTM | estimate)
Revenue
11,903.7% | 159.2%
EBITDA
65.6% | 53.3%
EBIT
65.2% | 54.3%
Net Income
59.9% | 52.8%
Free Cash Flow
14.5%
Margin (TTM | estimate)
Gross
97.8%
EBITDA
-47.4% | -40.4%
EBIT
-48.1%
Net
-53.5% | -41.3%
Free Cash Flow
-108.4%
More
EPS
$-0.1
FCF per Share
$-0.3
Short interest
11.2%
Employees
229
Rev per Employee
$340.0k
Show more

Is Geron Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Geron Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Geron Corporation forecast:

11x Buy
69%
4x Hold
25%
1x Sell
6%

Analyst Opinions

16 Analysts have issued a Geron Corporation forecast:

Buy
69%
Hold
25%
Sell
6%

Financial data from Geron Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
164 164
11,904% 11,904%
100%
- Direct Costs 3.64 3.64
18,100% 18,100%
2%
161 161
18,384% 18,384%
98%
- Selling and Administrative Expenses 158 158
49% 49%
96%
- Research and Development Expense 80 80
34% 34%
49%
-78 -78
66% 66%
-47%
- Depreciation and Amortization 1.13 1.13
22% 22%
1%
EBIT (Operating Income) EBIT -79 -79
65% 65%
-48%
Net Profit -88 -88
60% 60%
-54%

In millions USD.

Don't miss a Thing! We will send you all news about Geron Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Geron Corporation Stock News

Neutral
Business Wire
4 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted an equity award in the form of stock options to purchase 11,000,000 shares of common stock to Harout Semerjian, Geron's new President and Chief Executive Officer, as an inducement material to his acceptance of employment with Geron. The stock o...
Negative
Seeking Alpha
4 days ago
Geron's Q2'25 sales of Rytelo (imetelstat) show clear growth, with net product revenue rising to $49M and underlying demand up 17%. Recent performance dispels fears that Rytelo's market share has already peaked, echoing past misjudgments seen with AUPH. A run-up into an interim readout from IMpactMF, GERN's trial of imetelstat in myelofibrosis, could begin in H1'26, since results are expected i...
Neutral
Seeking Alpha
6 days ago
Geron Corporation (NASDAQ:GERN ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants & - Corporate Participant David Borah - Corporate Participant Dawn Carter Bir - Interim President & Chief Executive Officer and Director Harout Semerjian - Corporate Participant James Ziegler - Executive VP & Chief Commercial Officer Joseph Emile Eid - Executive Vice President of Res...
More Geron Corporation News

Company Profile

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.

Head office United States
CEO Dawn Bir
Employees 229
Founded 1990
Website www.geron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today